腾盛博药-B(02137)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02137 腾盛博药-B

已收盘 04-30 16:08:11

1.350

-0.040

-2.88%

最高1.400	最低1.340	成交量170.10万
今开1.390	昨收1.390	日振幅4.32%
总市值9.75亿	流通市值9.75亿	总股本7.22亿
成交额231.70万	换手率0.24%	流通股本7.22亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02137","market":"HK","secType":"STK","nameCN":"腾盛博药-B","latestPrice":1.35,"timestamp":1777536491343,"preClose":1.39,"halted":0,"volume":1701000,"delay":0,"changeRate":-0.028776978417266053,"floatShares":722000000,"shares":722000000,"eps":-0.3535164821175346,"marketStatus":"已收盘","change":-0.04,"latestTime":"04-30 16:08:11","open":1.39,"high":1.4,"low":1.34,"amount":2317015,"amplitude":0.043165,"askPrice":1.36,"askSize":14000,"bidPrice":1.35,"bidSize":39500,"shortable":0,"etf":0,"ttmEps":-0.3535164821175346,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777858200000},"marketStatusCode":5,"adr":0,"listingDate":1626105600000,"exchange":"SEHK","adjPreClose":1.39,"openAndCloseTimeList":[[1777512600000,1777521600000],[1777525200000,1777536000000]],"volumeRatio":1.446552,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02137","defaultTab":"news","newsList":[{"id":"2630382242","title":"腾盛博药-B(02137)在APASL 2026发表治疗结束后HBsAg反弹的跨研究分析结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2630382242","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630382242?lang=zh_cn&edition=full","pubTime":"2026-04-26 19:03","pubTimestamp":1777201422,"startTime":"0","endTime":"0","summary":"智通财经APP讯，腾盛博药-B 发布公告，本公司在2026年4月22至25日于土耳其伊斯坦布尔举行的第35届亚太肝病学会年会上，发表了一项关于治疗后乙肝表面抗原反弹特征的跨研究汇总分析结果。本次分析对两项研究的数据进行了汇总，以评估接受PEG-IFNα单药或联合 elebsiran或BRII-179治疗的参与者在EOT后HBsAg反弹的发生率、反弹幅度以及其临床相关性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434066.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02137","BK1574","BK1587","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121303809","title":"腾盛博药-B(02137)2025年收入达1860.5万元　HBV核心管线稳步推进亏损大幅收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1121303809","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121303809?lang=zh_cn&edition=full","pubTime":"2026-04-23 17:01","pubTimestamp":1776934915,"startTime":"0","endTime":"0","summary":"腾盛博药-B在2025年度聚焦高严重性疾病研发，HBV管线多项2b期临床研究取得阶段性进展，全年收入首次达到人民币1860.5万元，较上一年显著增长；年内亏损约为人民币2.24亿元，相比2024年的逾5亿元有明显收窄。以下为报告期内主要经营与财务表现概览：。2025年公司录得收入人民币1860.5万元，为首次实现收入入账；同时，其他收入约为6877.7万元，全年研发开支则为2.13亿元，较上一年有所下降。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"腾盛博药-B(02137)2025年收入达1860.5万元　HBV核心管线稳步推进亏损大幅收窄","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140470167","title":"腾盛博药-B授予董事股份购回授权，规模达已发行股本一成","url":"https://stock-news.laohu8.com/highlight/detail?id=1140470167","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140470167?lang=zh_cn&edition=full","pubTime":"2026-04-23 16:56","pubTimestamp":1776934601,"startTime":"0","endTime":"0","summary":"腾盛博药-B在最新公告中披露，董事会计划在即将召开的股东周年大会上寻求一般授权，回购不超过公司于相关决议案获通过当日已发行股份总数的10%。截至公告发布时间，公司已发行股份总数为721,806,998股，回购上限约为72,180,699股。董事会认为，此举有助于提升每股价值、增强股东回报和优化资本结构，符合公司及股东的整体最佳利益。董事会强调，将在不损害正常运营资金需求的前提下行使上述回购权，并呼吁股东于大会上审议相关提案。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"腾盛博药-B授予董事股份购回授权，规模达已发行股本一成","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629890703","title":"广发汇阳三个月定期开放债券基金经理变动：洪志不再担任该基金基金经理","url":"https://stock-news.laohu8.com/highlight/detail?id=2629890703","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629890703?lang=zh_cn&edition=full","pubTime":"2026-04-21 09:31","pubTimestamp":1776735095,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年4月21日，广发汇阳三个月定期开放债券（007256）发布公告，洪志不再担任该基金基金经理，离任日期为2026年4月21日，变更后广发汇阳三个月定期开放债券（007256）的基金经理为郎振东。截止2026年4月20日，广发汇阳三个月定期开放债券净值为1.1860，近一年上涨2.01%。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100016279.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","02137","BK1574","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627296309","title":"腾盛博药-B(02137)向位于美国的司法仲裁与调解服务公司提交针对Vir的仲裁申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2627296309","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627296309?lang=zh_cn&edition=full","pubTime":"2026-04-16 17:33","pubTimestamp":1776332012,"startTime":"0","endTime":"0","summary":"智通财经APP讯，腾盛博药-B 发布公告，2026年4月16日, 对于因合作协议和协议函引发的合同争议，腾盛博药向位于美国的司法仲裁与调解服务公司提交了针对Vir Biotechnology, Inc.的仲裁申请。集团将继续寻求法律意见，并采取必要措施以维护集团的最佳利益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429426.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","BK1587","02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144619357","title":"腾盛博药-B要求Vir移交Elebsiran生产权并索赔 指控其涉嫌违约","url":"https://stock-news.laohu8.com/highlight/detail?id=1144619357","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144619357?lang=zh_cn&edition=full","pubTime":"2026-04-16 17:32","pubTimestamp":1776331934,"startTime":"0","endTime":"0","summary":"腾盛博药-B（BRII-B）日前正式向Vir公司提出要求，主张其移交Elebsiran药物的生产技术及相关权益，并就涉嫌违约行为索赔相应损失。\n根据公开声明，腾盛博药-B指控Vir在合作过程中存在违反协议条款的行为。该公司寻求通过法律途径维护自身权益，要求Vir立即移交Elebsiran的完整生产工艺流程。\n此次纠纷涉及双方在生物制药领域的合作协议。腾盛博药-B强调，Vir的违约行为已对公司研发进度造成实质性影响。除生产技术移交外，该公司还要求Vir承担因违约导致的全部经济损失。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02137","BK1161","BK1574","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195379830","title":"腾盛博药-B公布3月股份变动月报表，已发行股份增加218,796股","url":"https://stock-news.laohu8.com/highlight/detail?id=1195379830","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195379830?lang=zh_cn&edition=full","pubTime":"2026-04-08 16:36","pubTimestamp":1775637402,"startTime":"0","endTime":"0","summary":"腾盛博药生物科技有限公司于2026年4月8日公告了截至2026年3月31日的股份变动月报表。根据报告期内信息，公司法定股本维持1,200,000,000股不变，每股面值为USD 0.000005，注册股本对应USD 6,000。报告期内，普通股已发行股份由上月底的721,540,793股增至721,759,589股，较此前增加218,796股；库存股份数目维持在12,723,500股不变。截至3月末，公司已发行股份总数为734,483,089股。根据期权及其他激励计划数据，本月合计行使股份期权增发178,000股，并通过奖励计划增发40,796股，合计新增218,796股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624662148","title":"猪价探底背后：行业全链有望重塑","url":"https://stock-news.laohu8.com/highlight/detail?id=2624662148","media":"中国经营网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624662148?lang=zh_cn&edition=full","pubTime":"2026-04-04 03:58","pubTimestamp":1775246320,"startTime":"0","endTime":"0","summary":"供需波动导致我国生猪价格持续下探，进而引发行业内外的广泛讨论。数据显示，截至3月底，全国外三元生猪均价在9.4元/公斤左右，同比降幅30%，比年初水平下降20%。多位行业人士告诉《中国经营报》记者，按全国平均水平，当前生猪养殖完全成本仍在13元/公斤左右，按出栏体重125公斤推算，意味着头均亏损450元左右。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604043695328679.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0187","BK0197","002458","BK0188","BK0183","BK0201","LU1655091616.SGD","BK0012","02137","BK0028","000876","02714","BK1161","002567","BK0238","BK0077","BK0194","BK0196","BK0039","BK0056","BK1574","BK1587","300498","BK1237","BK0195","002714","BK0240","002124","BK0070"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1101608081","title":"异动解读 | 业绩亏损收窄但收入低迷，腾盛博药-B盘中大跌5.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=1101608081","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101608081?lang=zh_cn&edition=full","pubTime":"2026-03-20 09:36","pubTimestamp":1773970597,"startTime":"0","endTime":"0","summary":"腾盛博药-B(02137.HK)今日盘中股价大跌5.48%，引起了市场的广泛关注。消息面上，公司于前一交易日盘后公布了2025年度业绩。数据显示，公司全年收入仅为1,861万元人民币，虽然亏损较上年同期的5.08亿元收窄至2.23亿元，每股亏损31分，且不派息，但整体业绩表现仍显疲弱。分析人士认为，尽管亏损有所收窄，但公司收入规模过小且持续处于亏损状态，可能未能达到市场预期，从而引发了投资者的担忧和抛售。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173598131","title":"腾盛博药-B (02137)2025年度业绩：实现0.018605亿元收入，亏损显著收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1173598131","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173598131?lang=zh_cn&edition=full","pubTime":"2026-03-19 19:09","pubTimestamp":1773918580,"startTime":"0","endTime":"0","summary":"腾盛博药-B  截至2025年12月31日止年度首次录得收入人民币0.018605亿元，主要来自许可费收入及技术转移协议信用取得的款项。同期年内亏损为人民币0.224067亿元，较上一年度的人民币0.512381亿元减少人民币0.288314亿元。报告期内，研究开支由上一年度的人民币0.249847亿元降至人民币0.212899亿元，主要源于第三方合约成本及雇员成本降低。行政开支则由人民币0.153155亿元降至人民币0.10945亿元，主要与员工成本及专业费用减少有关。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620024498","title":"腾盛博药-B(02137)发布年度业绩，股东应占亏损2.23亿元 同比收窄56.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620024498","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620024498?lang=zh_cn&edition=full","pubTime":"2026-03-19 19:04","pubTimestamp":1773918289,"startTime":"0","endTime":"0","summary":"智通财经APP讯，腾盛博药-B(02137)发布截至2025年12月31日止年度业绩，该公司取得收益人民币1860.5万元(单位下同)，去年同期收益为0元;公司拥有人应占年内亏损2.23亿元，同比收窄56.19%;每股亏损0.31元。公告称，收益增加主要归因于根据与健康元集团订立的知识产权许可及技术转让协议所收取的款项。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416054.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02137","BK1574","BK1587","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618976539","title":"腾盛博药-B盘中异动 早盘股价大跌5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618976539","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618976539?lang=zh_cn&edition=full","pubTime":"2026-03-11 09:33","pubTimestamp":1773192826,"startTime":"0","endTime":"0","summary":"2026年03月11日早盘09时33分，腾盛博药-B股票出现异动，股价快速下挫5.16%。截至发稿，该股报1.470港元/股，成交量15.7万股，换手率0.02%，振幅3.87%。机构评级方面，在所有1家参与评级的机构中，100%的券商给予持有建议，无券商给予买入、卖出建议。腾盛博药-B股票所在的生物技术行业中，整体跌幅为0.27%。腾盛博药-B公司简介：腾盛博药生物科技有限公司是一家主要从事感染性疾病以及中枢神经系统疾病治疗方法开发的生物科技公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311093346a6b6a031&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311093346a6b6a031&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02137","BK1574","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617682756","title":"每周股票复盘：清溢光电（688138）核心技术人员洪志华离职","url":"https://stock-news.laohu8.com/highlight/detail?id=2617682756","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617682756?lang=zh_cn&edition=full","pubTime":"2026-03-08 02:22","pubTimestamp":1772907732,"startTime":"0","endTime":"0","summary":"中信证券股份有限公司关于深圳清溢光电股份有限公司核心技术人员离职的核查意见深圳清溢光电股份有限公司核心技术人员洪志华先生因个人原因离职，已办理工作交接，不再担任公司任何职务。洪志华持有公司股票130,000股，任职期间参与的知识产权归属公司，无纠纷。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030800000705.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","02137","BK1587","BK0214","688138","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195745780","title":"腾盛博药-B（02137）2026年2月股份变动月报表：股本小幅增长7,750股","url":"https://stock-news.laohu8.com/highlight/detail?id=1195745780","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195745780?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:53","pubTimestamp":1772614382,"startTime":"0","endTime":"0","summary":"腾盛博药生物科技有限公司于2026年3月4日发布了2026年2月股份变动月报表，披露报告期内公司股本结构及股份变动情况。报告期内，公司法定/注册股本未发生变化，维持在1,200,000,000股，面值为每股USD 0.000005，总额为USD 6,000。期权与激励计划方面，首次公开发售股份激励计划、首次公开发售后购股权计划及2023年购股权计划在报告期内均有部分期权失效，但未有期权行使导致新股发行。截至2026年2月末，公司股本总数较上月末略有增加，整体维持稳定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616275559","title":"腾盛博药-B盘中异动 临近午盘快速下跌5.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616275559","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616275559?lang=zh_cn&edition=full","pubTime":"2026-03-04 11:35","pubTimestamp":1772595313,"startTime":"0","endTime":"0","summary":"2026年03月04日临近午盘11时35分，腾盛博药-B股票出现异动，股价快速下跌5.52%。截至发稿，该股报1.370港元/股，成交量77.1万股，换手率0.11%，振幅4.83%。腾盛博药-B股票所在的生物技术行业中，整体跌幅为3.37%。腾盛博药-B公司简介：腾盛博药生物科技有限公司是一家主要从事感染性疾病以及中枢神经系统疾病治疗方法开发的生物科技公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304113514a449592c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304113514a449592c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","02137","BK1161","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616035180","title":"腾盛博药-B盘中异动 早盘股价大跌5.77%报1.470港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616035180","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616035180?lang=zh_cn&edition=full","pubTime":"2026-03-02 09:56","pubTimestamp":1772416561,"startTime":"0","endTime":"0","summary":"2026年03月02日早盘09时56分，腾盛博药-B股票出现异动，股价快速下挫5.77%。截至发稿，该股报1.470港元/股，成交量86.4万股，换手率0.12%，振幅5.13%。资金方面，该股资金流入3.304万港元，流出125.695万港元。腾盛博药-B股票所在的生物技术行业中，整体跌幅为1.63%。腾盛博药-B公司简介：腾盛博药生物科技有限公司是一家主要从事感染性疾病以及中枢神经系统疾病治疗方法开发的生物科技公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302095601a43fdd71&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302095601a43fdd71&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02137","BK1574","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614008079","title":"腾盛博药-B02月26日主力净流出83.3万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2614008079","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614008079?lang=zh_cn&edition=full","pubTime":"2026-02-26 16:15","pubTimestamp":1772093754,"startTime":"0","endTime":"0","summary":"02月26日, 腾盛博药-B股价跌3.77%，报收1.53元，成交金额316.3万元，换手率0.28%，振幅4.40%，量比2.78。腾盛博药-B今日主力资金净流出83.3万元，上一交易日主力净流出0万元。该股主力净额占比0.07%，港股市场排名2615/2718。|02月26日主力加仓幅度排名||#|股票简称|主力净额占比|#|鸿盛昌资源|22.52%|#|美高域|2.21%|#|立高控股|1.78%|#|...|...|#2616|腾盛博药-B|-0.08%|（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226162018a4caa4b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226162018a4caa4b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1587","BK1574","02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611152962","title":"腾盛博药-B盘中异动 急速上涨5.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2611152962","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611152962?lang=zh_cn&edition=full","pubTime":"2026-02-13 14:36","pubTimestamp":1770964579,"startTime":"0","endTime":"0","summary":"2026年02月13日下午盘14时36分，腾盛博药-B股票出现波动，股价快速上涨5.37%。截至发稿，该股报1.570港元/股，成交量145.35万股，换手率0.20%，振幅7.38%。腾盛博药-B股票所在的生物技术行业中，整体跌幅为1.71%。其相关个股中，再鼎医药、腾盛博药-B、基石药业-B涨幅较大，振幅较大的相关个股有北海康成-B、荃信生物-B、华昊中天医药-B，振幅分别为10.45%、8.48%、8.40%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021314362097a60de0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021314362097a60de0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","02137","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610831699","title":"腾盛博药-B02月10日主力净流入177.7万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2610831699","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610831699?lang=zh_cn&edition=full","pubTime":"2026-02-10 16:15","pubTimestamp":1770711348,"startTime":"0","endTime":"0","summary":"02月10日, 腾盛博药-B股价涨5.41%，报收1.56元，成交金额396.7万元，换手率0.35%，振幅7.43%，量比2.19。腾盛博药-B今日主力资金净流入177.7万元，上一交易日主力净流出118.6万元。该股近5个交易日上涨4.70%，主力资金累计净流入59.1万元；近20日主力资金累计净流出235.1万元，其中净流出天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210162006a492a80f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210162006a492a80f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1587","BK1574","BK1161","02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195724843","title":"腾盛博药（2137）更新1月股份变动月报表 股本小幅增至约7.215亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=1195724843","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195724843?lang=zh_cn&edition=full","pubTime":"2026-02-04 17:15","pubTimestamp":1770196544,"startTime":"0","endTime":"0","summary":"腾盛博药生物科技有限公司于2026年2月4日公布截至2026年1月31日的月度股份变动情况。报告显示，公司注册股本本月维持1,200,000,000股，面值0.000005美元，总额6,000美元。期末已发行普通股数量约为721,533,043股，较上月增加355,981股，库存股数则保持不变，为12,723,500股。公司当月主要通过股份期权及其他股权激励计划增发股份。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02137"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.briibio.com","stockEarnings":[{"period":"1week","weight":-0.0733},{"period":"1month","weight":0},{"period":"3month","weight":-0.1203},{"period":"6month","weight":-0.2363},{"period":"1year","weight":-0.2872},{"period":"ytd","weight":-0.0142}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.055},{"period":"3month","weight":-0.0664},{"period":"6month","weight":0.0079},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.0188}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"腾盛博药生物科技有限公司是一家主要从事感染性疾病以及中枢神经系统疾病治疗方法开发的生物科技公司。该公司研发的产品主要包括乙型肝炎病（HBV）免疫治疗候选药物BRII-179、靶向乙型肝炎表面抗原（HBsAg）的研究性HBV中和单克隆抗体Tobevibart、以及用于治疗多重耐药性（MDR）和广泛耐药性（XDR）的革兰氏阴性菌感染的合成脂肽soralimixin（BRII-693）等。该公司主要在中国国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.040695},{"month":2,"riseRate":0.6,"avgChangeRate":0.049398},{"month":3,"riseRate":0.2,"avgChangeRate":-0.163076},{"month":4,"riseRate":0.4,"avgChangeRate":-0.009915},{"month":5,"riseRate":0,"avgChangeRate":-0.064507},{"month":6,"riseRate":0.25,"avgChangeRate":-0.093488},{"month":7,"riseRate":1,"avgChangeRate":0.097158},{"month":8,"riseRate":0.2,"avgChangeRate":0.004254},{"month":9,"riseRate":0.6,"avgChangeRate":-0.00155},{"month":10,"riseRate":0.2,"avgChangeRate":-0.127852},{"month":11,"riseRate":0.6,"avgChangeRate":0.286305},{"month":12,"riseRate":0.2,"avgChangeRate":-0.154392}],"exchange":"SEHK","name":"腾盛博药-B","nameEN":"BRII-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"腾盛博药-B(02137)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供腾盛博药-B(02137)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"腾盛博药-B,02137,腾盛博药-B股票,腾盛博药-B股票老虎,腾盛博药-B股票老虎国际,腾盛博药-B行情,腾盛博药-B股票行情,腾盛博药-B股价,腾盛博药-B股市,腾盛博药-B股票价格,腾盛博药-B股票交易,腾盛博药-B股票购买,腾盛博药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"腾盛博药-B(02137)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供腾盛博药-B(02137)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}